8-K: Curis Secures $7 Million Through Combined Stock and Warrant Offering to Extend Cash Runway into Early 2026

Curis, Inc. has announced a $7.0 million registered direct offering and concurrent private placement of common stock and warrants, aiming to fund operations into the first quarter of 2026 and advance its emavusertib clinical programs.

Summary

• Curis, Inc. entered into a Securities Purchase Agreement on July 2, 2025, for a combined registered direct offering and concurrent private placement.
• The offering includes 1,538,460 shares of common stock in a registered direct offering.
• The concurrent private placement involves unregistered pre-funded warrants to purchase up to 1,538,461 shares (exercise price $0.01 per share) and unregistered common warrants to purchase up to 3,076,921 shares (exercise price $2.15 per share).
• The combined purchase price for one share and an associated common warrant is $2.275, while for one pre-funded warrant and an associated common warrant, it is $2.265.
• Gross proceeds are expected to be approximately $7.0 million, before deducting placement agent fees and other offering expenses.
• The company expects the net proceeds, combined with existing cash and cash equivalents, to fund operations into the first quarter of 2026.
• The company terminated the prospectus for its at-the-market (ATM) offering program with Cantor Fitzgerald & Co. and JonesTrading Institutional Services LLC on July 1, 2025, having sold 188,316 shares for approximately $1.2 million gross proceeds under this program as of March 31, 2025.
• As of March 31, 2025, Curis had $20.3 million in cash, 10.5 million common shares outstanding, and 26.0 million fully diluted shares outstanding.

Sentiment

Score: 4

Explanation: While the capital raise provides necessary funding for ongoing operations and clinical programs, the relatively short cash runway extension (into Q1 2026) and the significant dilution from the offering indicate persistent financial challenges and a continued need for future capital. The positive clinical data for emavusertib offers potential, but the immediate financial outlook remains constrained.

Positives

• Successfully raised approximately $7.0 million in gross proceeds, providing additional capital for ongoing operations and clinical programs.
• The capital infusion is expected to extend the company's cash runway into the first quarter of 2026, addressing immediate funding needs.
• Emavusertib, the company's lead candidate, has shown encouraging clinical data in Non-Hodgkin Lymphoma (NHL) and Acute Myeloid Leukemia (AML), demonstrating anti-cancer activity and synergy with other therapies.
• Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for Primary Central Nervous System Lymphoma (PCNSL), AML, and Myelodysplastic Syndromes (MDS), and from the European Commission for PCNSL, which can expedite development and provide market exclusivity.
• The company anticipates releasing data from 30-35 PCNSL patients in Q4 2025, a key clinical milestone that could provide further validation for emavusertib.
• Composition of Matter Intellectual Property (IP) for emavusertib extends until 2035 (before potential extension), providing long-term protection for the asset.

Negatives

• The offering involves significant potential dilution through the issuance of new common stock and a substantial number of warrants, which could increase the total outstanding shares by over 6 million upon full exercise.
• The cash runway extension only reaches into the first quarter of 2026, indicating a relatively short funding horizon and a continued need for future capital raises.
• The termination of the at-the-market (ATM) offering program, while potentially a strategic shift, removes a flexible and continuous capital-raising mechanism.
• The company's estimate for cash runway is based on assumptions that 'may prove to be wrong,' and capital could be used sooner than currently expected, posing a financial risk.

Risks

• Risks and uncertainties related to market and other conditions may impact the completion of the offerings.
• There is no assurance that the company will be able to complete the offerings on the anticipated terms, or at all.
• General economic, industry, or political conditions in the United States or internationally could adversely affect the company's business and financial performance.
• The cash runway estimate is based on assumptions that may prove incorrect, potentially leading to a faster depletion of capital resources than anticipated.
• Forward-looking statements are subject to various risks and uncertainties, including those related to regulatory actions by the FDA or equivalent foreign agencies, clinical trial outcomes, and market acceptance of emavusertib.
• The company disclaims any intention or obligation to update any forward-looking statements after the date of the report, except as may be required by law.

Future Outlook

Curis expects the net proceeds from the current offerings, combined with its existing cash and cash equivalents, to fund its operations into the first quarter of 2026. The company anticipates releasing data from 30-35 PCNSL patients in Q4 2025. Future plans include continuing enrollment in PCNSL studies for potential Conditional and Accelerated Approval, working with regulatory bodies on confirmatory trial design, and prioritizing new NHL indications for expansion. For AML, with additional funding, the next step is a registrational head-to-head study versus gilteritinib.

Management Comments

• Curis intends to use the net proceeds from the offering on research, development, working capital, and other general corporate purposes.
• Based on the company’s research and development plans and timing expectations related to program progress, the net proceeds from the offerings (excluding proceeds from any exercise of Unregistered Warrants), together with existing cash and cash equivalents, are expected to fund operations into the first quarter of 2026.
• The company has based this estimate on assumptions that may prove to be wrong, and capital resources could be used sooner than currently expected.

Industry Context

This capital raise by Curis, a biotechnology company, is a common strategy in the industry to fund ongoing research and development, particularly for clinical-stage assets like emavusertib. The reliance on equity financing, including warrants, reflects the typical funding landscape for biotechs, which often operate at a loss for extended periods while developing drug candidates. The termination of an ATM program and subsequent direct offering suggests a strategic shift in capital raising, possibly seeking larger, more structured infusions of capital from institutional investors rather than continuous smaller raises. The focus on oncology (NHL, AML, Solid Tumors) aligns with a high-value therapeutic area, but also one with significant R&D costs and competitive pressures.

Comparison to Industry Standards

• The capital raise of $7.0 million is relatively modest for a clinical-stage biotechnology company, especially given the high costs associated with drug development and clinical trials.
• A cash runway extending only into Q1 2026 (approximately 6-9 months from the filing date) is considered short by industry standards, typically indicating a need for further capital raises in the near future. Many biotech companies aim for 12-18 months of runway to avoid frequent fundraising and associated dilution.
• The issuance of warrants alongside common stock is a common practice in biotech financing to make offerings more attractive to investors, providing additional upside potential.
• The liquidated damages clause in the Registration Rights Agreement (1.0% per 30-day period for registration failures, capped at 6.0%) is a standard investor protection mechanism in private placements, ensuring timely registration of resale shares.
• The beneficial ownership limitations (4.99%/9.99% initially, up to 9.99%/19.99%) are typical provisions to prevent immediate triggering of change-of-control clauses or hostile takeover defenses.

Stakeholder Impact

• Shareholders: Existing shareholders will experience significant dilution due to the issuance of new common stock and warrants. The short cash runway implies potential for further dilution in the near future.
• Investors (Purchasers in Offering): These institutional investors gain exposure to Curis's pipeline, particularly emavusertib, with the potential for upside from warrant exercise, but also bear the risk of clinical trial outcomes and future dilution.
• Employees: Continued funding supports ongoing research and development, potentially providing job security and continuity for employees involved in the emavusertib programs.
• Creditors: The capital raise improves the company's liquidity position, potentially reducing immediate credit risk.
• Patients: Continued funding enables the advancement of emavusertib's clinical trials, potentially leading to new treatment options for patients with NHL, AML, and solid tumors.

Next Steps

• Closing of the registered direct offering and concurrent private placement on or before July 3, 2025.
• Company to file a Current Report on Form 8-K, including the Transaction Documents as exhibits.
• Company to file a prospectus supplement with the SEC for the registered direct offering.
• Company to file a registration statement covering the resale of Warrant Shares no later than 60 days following the closing of the Private Placement.
• Continue enrollment in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) for PCNSL patients.
• Release data from 30-35 PCNSL patients in Q4 2025.
• Work with EMA and FDA on confirmatory trial design in PCNSL.
• Prioritize next NHL indications for expansion.
• With additional funding, initiate a registrational head-to-head study vs. gilteritinib for FLT3m AML.

Key Dates

Recommendation

Keywords

Curis Inc., CRIS, Biotechnology, SEC Filing, 8-K, Capital Raise, Registered Direct Offering, Private Placement, Common Stock, Warrants, Pre-Funded Warrants, Emavusertib, IRAK4 Inhibitor, Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, PCNSL, AML, Orphan Drug Designation, Clinical Trials, Cash Runway, Dilution, Nasdaq Capital Market